DelistingJun 8, 2026, 04:07 PM
aTyr Pharma Gets 180-Day Extension to Meet Nasdaq Bid Price Rule
AI Summary
aTyr Pharma Inc. has been granted an additional 180-day period by Nasdaq, until November 30, 2026, to regain compliance with the minimum bid price requirement of $1.00 per share. The company had initially received a deficiency notice for failing to meet this requirement. Nasdaq has confirmed that aTyr Pharma meets all other listing standards, and the company intends to cure the deficiency, possibly through a reverse stock split. Failure to comply by the new deadline could lead to the delisting of its common stock from The Nasdaq Capital Market.
Key Highlights
- aTyr Pharma received a second 180-day extension until November 30, 2026, to regain Nasdaq minimum bid price compliance.
- The company previously received a deficiency notice for closing bid price below $1.00.
- Nasdaq determined aTyr Pharma meets other listing requirements, including market value of publicly held shares.
- aTyr Pharma intends to cure the deficiency, potentially through a reverse stock split.
- Failure to comply by November 30, 2026, will result in delisting, with a potential appeal process.
Price Impact
More from ATYR